- 1 Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality
- 2 in residents of Long-Term Care Facilities in the VIVALDI study
- 3
- 4 Oliver Stirrup¹, Madhumita Shrotri², Natalie L. Adams², Maria Krutikov², Borscha Azmi², Igor Monakhov³,
- 5 Gokhan Tut⁴, Paul Moss⁴, Andrew Hayward^{5,6}, Andrew Copas¹, Laura Shallcross²
- 6
- 7 ¹ Institute for Global Health, University College London, London, UK
- 8 ² UCL Institute of Health Informatics, London, UK
- 9 ³ UK Health Security Agency, London, UK
- 10 ⁴ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
- 11 ⁵ UCL Institute of Epidemiology & Healthcare, London, UK
- 12 ⁶ Health Data Research UK, London, UK
- 13
- 14 Correspondence to: Dr Oliver Stirrup, UCL Institute for Global Health, 222 Euston Road, London NW1 2DA,
- 15 UK. oliver.stirrup@ucl.ac.uk
- 16 Alternate corresponding author: Laura Shallcross, UCL Institute of Health Informatics, 222 Euston Road,
- 17 London NW1 2DA, UK. l.shallcross@ucl.ac.uk
- 18
- 19 Keywords: SARS-CoV-2; COVID-19; Omicron; Vaccine effectiveness; long-term care facilities.
- 20 Running title: Booster vaccines in older care residents
- 21 Author contributions: OS conducted statistical analyses and drafted Methods and Results, with MS and AC
- 22 23 contributing to coding of data processing and analysis. NLA contributed to Introduction and Discussion. MK,

BA, GT, PM, AH, AC and LS are involved in the planning, recruitment and organisation of the Vivaldi cohort 24

- study. IM worked on data processing and linkage. GT and PM conduct lab work for the study. LS, AC, AH 25 obtained funding for the study. All authors contributed to the planning and interpretation of this analysis, and
- 26 contributed to the final manuscript draft.

27 Abstract

- 28 We evaluated the effectiveness of 1-3 booster vaccinations against SARS-CoV-2 related mortality
- among a cohort of 13407 older residents of long-term care facilities (LTCFs) participating in the
- 30 VIVALDI study in England in 2022. Cox regression was used to estimate relative hazards of SARS-
- 31 CoV-2 related death following booster vaccination relative to 2 doses (after 84+ days), stratified by
- 32 previous SARS-CoV-2 infection and adjusting for age, sex and LTCF capacity. Each booster
- 33 provided additional short-term protection relative to primary vaccination, with consistent pattern of
- 34 waning to 45-75% reduction in risk beyond 112 days.

35

36 Introduction

- 37 Long-term care facilities (LTCFs) in the UK were severely impacted by COVID-19 early in the
- 38 pandemic[1]. As such, LTCF staff and residents were prioritised for primary vaccination against
- 39 SARS-CoV-2 starting in December 2020[2] and for additional rounds of booster vaccination from
- 40 September 2021, March 2022 and September 2022.
- 41 We previously reported waning of protection against infection and severe clinical outcomes following
- 42 primary course vaccination in LTCF residents from 84 days (12 weeks) following second dose [3],
- 43 with an improvement in protection against severe outcomes observed following first booster vaccine
- 44 dose (third dose)[3] that remained after emergence of the Omicron variant[4]. This study aims to
- 45 produce an updated evaluation of the effectiveness of third, fourth and fifth dose booster vaccination
- 46 against SARS-CoV-2 associated death amongst residents of LTCFs in England over the year 2022.
- 47 We focused on the outcome of mortality because of changes to testing policy in LTCFs in the UK
- 48 within the period analysed, which make it challenging to analyse effects on SARS-CoV-2 infection
- 49 incidence or to evaluate hospital admissions in a timely manner.

50 Methods

51 VIVALDI is a prospective cohort study investigating SARS-CoV-2 in LTCF residents and staff in 52 England [5]. For this study, the analysis period is defined from January 1 2022 to 31 December 2022, 53 and residents aged >65 years were eligible for inclusion if they had at least one polymerase chain 54 reaction (PCR) or lateral flow device (LFD) result linked to a participating LTCF available within this 55 period. Following national guidelines, residents underwent monthly routine PCR testing until the end 56 of March 2022, when the policy switched to symptomatic and outbreak testing only. The analysis 57 period was chosen to allow our prior estimates of vaccine effectiveness to be updated whilst retaining 58 a period when asymptomatic testing was still in use, allowing identification of the cohort of residents 59 in participating LTCFs in early 2022. As previously, we excluded individuals who had not received at

60 least two vaccine doses before the analysis period[4] because unvaccinated residents are substantially

61 more likely to be receiving end of life care.

62	As previously we retrieved all available PCR and LFD results from the national testing programme
63	through the COVID-19 Datastore. Test results and vaccination (National Immunisation Management
64	Service) and mortality (Office for National Statistics) data from national records were linked to study
65	participants using pseudo-identifiers based on National Health Service (NHS) numbers[3]. COVID-19
66	death was defined as death within 28 days of positive PCR or LFD test or with COVID-19 recorded
67	as primary or secondary cause of death on the death certificate. SARS-CoV2 serological test results
68	for IgG antibodies to the nucleocapsid protein (Abbott ARCHITECT system (Abbott, Maidenhead,
69	UK)) were linked in a subset of participants who consented to blood sampling specifically for the
70	VIVALDI study[6].

71

72 Statistical analysis

73 We examined individual-level vaccine effectiveness against SARS-CoV-2 associated death.

74 Individuals were eligible for inclusion if they had complete data on sex and age, had received at least

75 2 vaccine-doses 84 days before analysis start date, had at least one PCR or LFD test result recorded

76 within the analysis period and were linked to a LTCF participating in VIVALDI with data on total

number of staff and residents. Individuals with third vaccine dose recorded before September 14

78 2021, fourth dose before March 21 2022 and fifth dose before September 5 2022 were excluded as

these dates corresponded to national roll-out to residents of these doses.

80

81 We used Cox regression models to derive adjusted hazard ratios (HRs) for risk of SARS-CoV-2

82 linked death. Vaccination status was included as a time-varying covariable. The reference category

83 was 2 vaccine doses, with \ge 84 days elapsed from Dose 2 (although this was varied to create graphical

summaries of the estimated effect of successive doses). Exposure categories were 0–13, 14–48, 49–

- 85 83, 84-111, 112-139 and \geq 140 days following Dose 3 and Dose 4, and 0–13, 14–48, 49–83 and \geq 84
- 86 days following Dose 5. Individuals entered the risk period on 1 January 2022, or date of their first

87	recorded PCR/LFD result within VIVALDI if later. Individuals with positive PCR/LFD result within
88	30 days prior to 1 January 2022 entered the risk period from the 31st day post-positive test.
89	Individuals exited the risk period at the earliest of: death or end of analysis period. Individuals were
90	additionally censored at 29 days post-positive SARS-CoV-2 test if they survived to this point;
91	COVID-related death from the original infection would be possible beyond this time but the
92	individual would also be at lower risk for a new SARS-CoV-2 infection, and so censoring at 29 days
93	was chosen to match our mortality outcome definition. Baseline hazard was defined over calendar
94	time. 95% CIs were calculated using robust SEs accounting for dependence of infection events within
95	LTCFs. Analysis was stratified by evidence of SARS-CoV2 infection prior to the risk period. We
96	adjusted for sex (binary variable), age (5-knot restricted cubic spline term) and LTCF size expressed
97	as total number of beds (linear term). All statistical analyses were conducted using STATA 17.0.
98	
99	Patient Consent Statement
100	Patient consent was not obtained for data use other than for those patients who underwent blood
101	sampling specifically for the VIVALDI study. The legal basis to access data from residents without
102	informed consent is provided by Health Research Authority Confidentiality Advisory Group approval
103	(21/CAG/0156). Ethical approval was obtained from South Central-Hampshire B Research Ethics
104	Committee (20/SC/0238).

105

106 Results

107 13407 residents from 327 LTCFs were included, following exclusion of 1051 because 2-dose
108 vaccination had not been completed more than 84 days before start of the analysis period, 194
109 because booster vaccination doses were recorded prior to national roll-out and 904 for whom a
110 positive SARS-CoV-2 test was recorded on the first day of their at-risk period. 3411 residents
111 (25.4%) had recorded evidence of SARS-CoV-2 infection prior to the analysis period. The median

age was 86.6 years (IQR, 80.2-91.8). 4132 residents died during the analysis period, of which 428

113 were associated with SARS-CoV-2.

114 12072 (90.0%) residents had received third-dose booster vaccination dose prior to the analysis period, 115 and 13104 (97.7%) by the end (98.8% of those surviving to year-end) (Figure 1). First booster doses 116 were Pfizer in the majority (n=12474, 95.2%), with Moderna also used (n=593, 4.5%). Second 117 boosters (fourth dose) had been received by 10846 (80.9%, 93.0% of survivors) and third boosters 118 (fifth dose) by 7311 (54.5%, 70.8% of survivors) of residents by end of analysis period. The majority 119 were Moderna vaccines for second booster (6421 (59.2%)) and for third booster (5991 (81.9%)). 120 8621 (64.3%) residents had received a bivalent vaccine by end of study period, mostly as third booster 121 dose but in some as first (n=120) or second (n=1455) booster received. 122 123 In residents without known prior SARS-CoV-2 infection, first booster reduced risk of SARS-CoV-2 124 linked death after 0-13 days (none observed), 14-48 days (HR 0.20, 0.07-0.58), 49-83 days (0.25, 125 (0.13-0.47) and (0.30, 0.18-0.51), with some apparent waning in level of protection by 126 112-139 days (0.44, 0.28-0.69) and 140+ days (0.38, 0.24-0.61) (Figure 2, Table 1). A similar pattern 127 was observed following fourth and fifth dose vaccination, although confidence intervals for HRs were 128 wider for fourth dose beyond 84 days and for fifth dose (Figure 2d) because of lower available 129 follow-up time and lower incidence of SARS-CoV-2 infection in the latter half of 2022. Residents 130 with known infection prior to the analysis period were at reduced risk of death relative to those 131 without prior infection (0.55,0.28-1.08; among those with 2-dose vaccination). Within this group, the 132 pattern of further protection from booster vaccination was similar to those without known prior 133 infection, although there is greater uncertainty in estimates. Adding a parameter to the model 134 representing receipt of a bivalent (BA.1) vaccine indicated possible greater protection but with a wide 135 confidence interval (0.81, 0.29-2.25). 136

137 Discussion

138	We found evidence that third, fourth and fifth dose booster vaccination provide additional short-term
139	protection against SARS-CoV-2 linked mortality among LTCF residents, relative to primary
140	vaccination only. This is consistent with data on fourth dose vaccination of LTCF residents in the
141	USA[7] and Canada[8]. The pattern of waning of protection appeared to be similar for successive
142	booster doses, stabilising at a 45-75% reduction in risk beyond 112 days (16 weeks).

143 Our data suggest that the combination of booster vaccination with prior SARS-CoV-2 infection

144 provides particularly strong protection against subsequent mortality from the virus, in line with

145 previous studies in the general population[9]. We are likely to have underestimated the protective

146 effect of prior infection in this analysis, as we have previously found the cumulative incidence of

147 detected SARS-CoV-2 infection to be substantially higher among residents who have undergone

148 testing for anti-nucleocapsid antibodies[6]. This suggests that many of the 'unexposed' group in our

analyses may have in fact been infected prior to the risk period, although the prevalence of prior

150 infection may be lower in residents who were admitted to care homes in the second half of 2021 and

151 2022 compared to those resident since 2020.

152 It is possible that the primarily bivalent fifth dose vaccination provided some additional long-term

153 protection, but the pattern of reduction in risk over time did not differ markedly from that observed

154 for prior booster doses. This is consistent with data from the general population in the USA[10],

155 perhaps due to the fact that different Omicron sub-lineages were circulating by the time that bivalent

156 vaccines based on the BA.1 lineage were rolled out[11].

157

158 Funding

159 This work is independent research funded by the Department of Health and Social Care (COVID-19

surveillance studies). MK is funded by a Wellcome Trust Clinical PhD Fellowship (222907/Z/21/Z). LS is

- 161 funded by a National Institute for Health Research Clinician Scientist Award (CS-2016-007). AH is supported
- 162 by Health Data Research UK (LOND1), which is funded by the UK Medical Research Council, Engineering and
- 163 Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social
- 164 Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health
- 165 and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern
- 166 Ireland), British Heart Foundation, and Wellcome Trust.

167 Potential Conflicts of Interest

- 168 LS reports grants from the Department of Health and Social Care during the conduct of the study and is a
- 169 member of the Social Care Working Group, which reports to the Scientific Advisory Group for Emergencies.
- 170 AH reports funding from the COVID Core Studies Programme and is a member of the New and Emerging
- 171 Respiratory Virus Threats Advisory Group at the Department of Health and Environmental Modelling Group of
- 172 the Scientific Advisory Group for Emergencies. All other authors declare no competing interests.

173

174 Acknowledgements

- 175 We thank the staff and residents in the long-term care facilities who participated in this study and Mark
- 176 Marshall at National Health Service (NHS) England who pseudonymised the electronic health records. The
- 177 views expressed in this publication are those of the authors and not necessarily those of the NHS or the UK
- 178 Health Security Agency.
- 179

180 References

- Chudasama DY, Milbourn H, Nsonwu O, et al. Penetration and impact of COVID-19
 in long term care facilities in England: population surveillance study. Int J Epidemiol
 2022; 50(6): 1804-13.
- 1842.Department of Health and Social Care. Independent report. Priority groups for
- 185 coronavirus (COVID-19) vaccination: advice from the JCVI, 30 December 2020.
 186 Available at: <u>https://www.gov.uk/government/publications/priority-groups-for-</u>
- 187 <u>coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020</u>. Accessed
 188 14 April 2022.

189	3.	Shrotri M, Krutikov M, Nacer-Laidi H, et al. Duration of vaccine effectiveness
190		against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of
191		long-term care facilities in England (VIVALDI): a prospective cohort study. The
192		Lancet Healthy Longevity 2022; 3(7): e470-e80.
193	4.	Stirrup O, Shrotri M, Adams NL, et al. Clinical Effectiveness of SARS-CoV-2
194		Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care
195		Facilities: A Prospective Cohort Study (VIVALDI). Open Forum Infectious Diseases
196		2022; 10(1).
197	5.	Krutikov M, Palmer T, Donaldson A, et al. Study Protocol: Understanding SARS-
198		Cov-2 infection, immunity and its duration in care home residents and staff in
199		England (VIVALDI). Wellcome Open Res 2020; 5: 232.
200	6.	Krutikov M, Palmer T, Tut G, et al. Prevalence and duration of detectable SARS-
201		CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over
202		the first year of the pandemic (VIVALDI study): prospective cohort study in England.
203		The Lancet Healthy Longevity 2022 ; 3(1): e13-e21.
204	7.	McConeghy KW. Effectiveness of a second COVID-19 vaccine booster dose against
205		infection, hospitalization, or death among nursing home residents—19 States, March
206		29–July 25, 2022. MMWR Morbidity and Mortality Weekly Report 2022; 71.
207	8.	Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19
208		mRNA vaccine against the omicron variant among long term care residents in
209		Ontario, Canada: test negative design study. BMJ 2022; 378: e071502.
210	9.	Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2
211		infection and hybrid immunity against the omicron variant and severe disease: a
212		systematic review and meta-regression. The Lancet Infectious Diseases 2023.
213	10.	Link-Gelles R. Effectiveness of bivalent mRNA vaccines in preventing symptomatic
214		SARS-CoV-2 infection—increasing community access to testing program, United
215		States, September–November 2022. MMWR Morbidity and Mortality Weekly Report
216		2022; 71.
217	11.	Offit PA. Bivalent Covid-19 Vaccines — A Cautionary Tale. New England Journal of
218		Medicine 2023 ; 388(6): 481-3.

219

220 Figures

Figure 1 Plot of booster vaccination status of residents of long term care facilities included in the

- analysis. The percentage of residents with each number of vaccine doses is given among those in
- 223 follow-up for the analysis at any given point in time.
- Figure 2 Plot of estimated hazard ratio (HR) for SARS-CoV-2 linked death (within 28 days of a
- 225 positive PCR or LFD test, and/or recorded on death certificate) following receipt of booster vaccine
- doses, among long term care facility residents without evidence of prior SARS-CoV-2 infection (a-c)
- and in those with prior SARS-CoV-2 infection (d). Results are shown for 3-5 doses relative to 2-dose
- vaccination in (a) and (d), for 4 doses relative to 3 doses beyond 140 days in (b) and for 5 doses
- relative to 4 doses beyond 140 days in (c).

230

- 231
- 232

233 Tables

- 234 Table 1 Crude event rates and adjusted hazard ratios against SARS-CoV-2 associated death
- 235 (within 28 days of a positive PCR or LFD test, and/or recorded on death certificate) for LTCF
- 236 residents, by prior SARS-CoV-2 exposure, and vaccination status

SARS-CoV-2 mortality						
Prior SARS- CoV-2 exposure	Vaccination status	Person- days	Deaths	IR /1000pd	HR (95% CI)*	HR (95% CI) *
Unexposed	D2 84+d	71837	35	0.49	Ref.	
	D3 0-13d	6471	0	0	0.00 (0.00-0.00)	
	D3 14-48d	39206	4	0.1	0.20 (0.07-0.58)	
	D3 49-83d	115192	15	0.13	0.25 (0.13-0.47)	
	D3 84-111d	193274	39	0.2	0.30 (0.18-0.51)	
	D3 112-139d	189472	50	0.26	0.44 (0.28-0.69)	
	D3 140+d	432958	81	0.19	0.38 (0.24-0.61)	
	D4 0-13d	66886	2	0.03	0.06 (0.01-0.25)	
	D4 14-48d	176815	10	0.06	0.16 (0.07-0.33)	
	D4 49-83d	168385	15	0.09	0.24 (0.11-0.54)	
	D4 84-111d	119450	14	0.12	0.28 (0.12-0.63)	
	D4 112-139d	92701	16	0.17	0.57 (0.27-1.20)	
	D4 140+d	90740	11	0.12	0.32 (0.15-0.68)	
	D5 0-13d	43722	1	0.02	0.05 (0.01-0.35)	
	D5 14-48d	114653	8	0.07	0.12 (0.05-0.29)	
	D5 49-83d	99414	10	0.1	0.26 (0.11-0.66)	
	D5 84+d	41549	5	0.12	0.25 (0.08-0.77)	
Exposed	D2 84+d	40015	11	0.27	0.55 (0.28-1.08)	Ref.
	D3 0-13d	3932	0	0		—
	D3 14-48d	20433	0	0		—
	D3 49-83d	51452	4	0.08		0.27 (0.09-0.86)
	D3 84-111d	81134	13	0.16		0.45 (0.20-0.98)
	D3 112-139d	78516	8	0.1		0.31 (0.12-0.85)
	D3 140+d	174497	12	0.07		0.26 (0.11-0.59)
	D4 0-13d	29654	0	0		—
	D4 14-48d	78026	2	0.03		0.13 (0.03-0.58)
	D4 49-83d	74409	1	0.01		0.07 (0.01-0.54)
	D4 84-111d	52959	3	0.06		0.24 (0.06-0.98)
	D4 112-139d	40544	2	0.05		0.30 (0.06-1.43)
	D4 140+d	38498	6	0.16		0.81 (0.28-2.33)
	D5 0-13d	19276	0	0		
	D5 14-48d	49902	2	0.04		0.12 (0.03-0.60)
	D5 49-83d	43712	4	0.09		0.45 (0.12-1.65)
	D5 84+d	19395	4	0.21		0.79 (0.20-3.07)

*HR values in the two columns are from mathematically identical statistical models, but HRs in right-hand

238 column are expressed relative to 'D2 84+d' vaccine status in individuals with prior SARS-CoV-2 infection.



